Drug intelligence / Profile preview

MiHA mRNA-electroporated donor dendritic cell vaccine

Development stage: Unknown
Lead developer: Radboud University Medical Center
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

The **MiHA mRNA-electroporated donor dendritic cell vaccine** is an experimental, ex vivo-generated cellular immunotherapy developed by the Radboud University Nijmegen Medical Centre (Radboud UMC). It consists of donor-derived dendritic cells (DCs) that are electroporated with mRNA encoding hematopoietic-restricted minor histocompatibility antigens (MiHAs), such as HA-1 or LRH-1. Administered intravenously to patients following HLA-matched allogeneic stem cell transplantation (allo-SCT) for hematologic malignancies, the vaccine is designed to selectively boost graft-versus-tumor (GVT) immunity. By presenting these hematopoietic-restricted MiHAs, the vaccine stimulates and expands donor-derived CD8+ cytotoxic T cells to target and eliminate residual leukemia or lymphoma cells without triggering graft-versus-host disease (GvHD).

Other names: MiHA-loaded donor dendritic cell vaccineMiHA mRNA transfected dendritic cell productMiHA-loaded donor dendritic cell vaccinationMiHA-loaded donor DC vaccine

Targets

Minor histocompatibility antigen peptide-human leukocyte antigen complexesCD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on MiHA mRNA-electroporated donor dendritic cell vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MiHA mRNA-electroporated donor dendritic cell vaccine.

Explore the full profile